Conference Proceedings
Immediate, Complete, and Sustained Inhibition of C5 with ALXN1210 Reduces Complement- Mediated Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Interim Analysis of a Dose-Escalation Study
Jong-Wook Lee, Eric Scott Bachman, Rasha Aguzzi, Jun Ho Jang, Jin Seok Kim, Scott T Rottinghaus, Lori Shafner, Jeff Szer
BLOOD | AMER SOC HEMATOLOGY | Published : 2016
Abstract
Abstract Background: ALXN1210 is a humanized monoclonal antibody designed for rapid, complete, sustained inhibition of C5 with less frequent dosing. A previous study in healthy volunteers demonstrated immediate, complete, and sustained C5 inhibition. The terminal half-life of ALXN1210 is approximately 3-4x longer than eculizumab, thus providing continuous suppression of hemolysis with an extended dosing interval. Aims: ALXN1210-PNH-103 is a Phase 1/2, multicenter, open-label, intrapatient dose-escalation study (NCT02598583), evaluating the safety, tolerability, and efficacy of 2 IV maintenance dosing regimens of ALXN1210 in patients (pts) ≥18 y w..
View full abstractGrants
Funding Acknowledgements
Lee: Alexion Pharmaceuticals, Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Bachman: Alexion Pharmaceuticals, Inc.: Employment. Aguzzi: Alexion Alexion Pharmaceuticals, Inc: Consultancy, Honoraria, Research Funding. Rottinghaus: Alexion Pharmaceuticals, Inc.: Employment. Shafner: Alexion Pharmaceuticals, Inc.: Employment. Szer: Ra Pharma: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alexion Pharmaceuticals, Inc.: Honoraria, Membership on an entity's Board of Directors or advisory committees; Alnylam: Honoraria, Membership on an entity's Board of Directors or advisory committees.